Biogen prepares for large layoffs after disastrous Aduhelm rollout
A company once owned by Martin Shkreli will pay $40 million to settle allegations it jacked up the price of a life-saving drug by 4,000%.
Asthma drug study failed to include children who could benefit most
The study tested Dupixent for asthma attacks in mostly white children, even though asthma takes a disproportionate toll on Black children.
AbbVie unit to pay $200 million to resolve closely watched opioid lawsuit in New York
Allergan will pay up to $200 million to resolve allegations made by New York state and two counties that it helped fuel the opioid crisis.
Pfizer’s vaccine chief on Omicron, boosters, and preparing for the unknown
STAT spoke with Pfizer’s head of vaccine research, Kathrin Jansen, about the latest data on the company’s vaccine and Omicron.
Archaic in-person exam law is holding back digital prescribing
A 2008 law aimed at stopping opioid “pill mills” is an unnecessary barrier to digital prescribing by virtual-first care companies.
Biogen’s reckoning: How the Aduhelm debacle pushed it to the brink
Aduhelm was the tipping point for Biogen’s turmoil, but STAT’s reporting reveals much deeper problems at the company.
A public health expert passes on football’s full body collisions for youths
Public health expert Kathleen Bachynski discusses the risks taken by youngsters playing football and other sports with full-body collisions.
Syrian refugee is thriving five years after last-gasp gene therapy
Positive follow-up data has helped move forward a clinical trial of the approach, offering hope to the 500,000 epidermolysis bullosa patients.
The UN must get on with appointing its new science board
The decision to appoint a board of advisors is welcome — and urgent, given the twin challenges of COVID and climate change.
Harnessing the body’s natural killers to target cancer
Natural killer cells, the body’s first line of defence against emerging cancers, could be engineered into powerful, off-the-shelf cancer therapies.